Omadacycline

Omadacycline
Clinical data
Pronunciationoh mad" a sye' kleen
Trade namesNuzyra
Other namesPTK-0796,[1] BAY 73-6944
AHFS/Drugs.comMonograph
MedlinePlusa618066
License data
Routes of
administration		By mouth, intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H40N4O7
Molar mass556.660 g·mol−1
3D model (JSmol)
  • CC(C)(C)CNCc1cc(c2c(c1O)C(=O)C3=C([C@]4([C@@H](C[C@@H]3C2)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)N(C)C
  • InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34,36-37,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
  • Key:JEECQCWWSTZDCK-IQZGDKDPSA-N

Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass[3] of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.[2][4]

Mechanism of action

The mechanism of action of omadacycline is similar to that of other tetracyclines – inhibition of bacterial protein synthesis. Omadacycline has activity against bacterial strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection).[5]

History

Omadacycline was invented at Tufts University School of Medicine by a research team led by Mark L. Nelson with Mohamed Ismail while at Tufts and Kwasi Ohemeng and Laura Honeyman at Paratek Pharmaceuticals, Boston. The team applying their chemistry methods to the tetracycline scaffolds created over 3000 new derivatives, leading to the novel third-generation compounds omadacycline and sarecycline.[6]

In vitro studies

In vitro studies have shown that omadacycline has activity against a broad range of Gram-positive and select Gram-negative pathogens.[7] Omadacycline has potent in vitro activity against Gram-positive aerobic bacteria including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant and multi-drug resistant Streptococcus pneumoniae, and vancomycin-resistant Enterococcus. Omadacycline also has antimicrobial activity against common Gram-negative aerobes, some anaerobes, and atypical bacteria such as Legionella and Chlamydia.[8] This activity translated to potent efficacy for omadacycline in an in vivo systemic infection model in mice.[9]

Additional in vitro and in vivo studies of omadacycline metabolism, disposition, and drug interactions show that omadacycline is metabolically stable (i.e., it does not undergo significant biotransformation) and neither inhibits nor interacts with metabolizing enzymes or transporters.[10]

Clinical trials

A phase II study was conducted comparing the safety and efficacy of omadacycline to linezolid for the treatment of complicated skin and skin structure infections. Patients were randomized at 11 sites in the US to receive either omadacycline 100 mg intravenously once daily with an option to transition to 200 mg orally once daily or linezolid 600 mg intravenously twice daily with an option to transition to 600 mg orally twice daily. The results indicated that omadacycline is well tolerated and has the potential to be an effective treatment in patients with complicated skin and skin structure infections.[11]

In June 2013, the US Food and Drug Administration (FDA) designated the intravenous and oral formulations of omadacycline as a qualified infectious disease product in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.[12]

A 650-patient phase III registration study comparing omadacycline to linezolid for the treatment of acute bacterial skin and skin structure infections began in June 2015.[13][14] Omadacycline met the primary efficacy endpoint of early clinical response with statistical non-inferiority (10% margin) compared to linezolid, and was generally safe and well tolerated. The most common treatment-emergent adverse events were gastrointestinal side effects (18.0% for omadacycline vs. 15.8% for linezolid).[15]

A 750-patient phase III study comparing omadacycline to moxifloxacin for the treatment of community-acquired bacterial pneumonia began in November 2015.[16] Omadacycline was statistically non-inferior to moxifloxacin at the early clinical response, 72 to 120 hours after therapy was initiated.[17]

In May 2016, a phase Ib study of omadacycline in urinary tract infection was initiated.[18]

In August 2016, a second phase III study of omadacycline was initiated in patients with acute bacterial skin and skin structure infections, comparing the efficacy and safety of once-daily, oral omadacycline to that of twice-daily, oral linezolid.[19] In July 2017, analysis of the data showed that all of the primary and secondary endpoints required for submission to the FDA and EMA were met. This was the third phase 3 registration study of omadacycline with favorable results.[20]

References

  1. ^ Boggs J. "Antibiotic Firm Paratek Joins IPO Queue; Aiming for $92M". bioworld.com. Clarivate Analytics. Archived from the original on 18 October 2017. Retrieved 17 October 2017.
  2. ^ a b "Nuzyra- omadacycline injection, powder, lyophilized, for solution; Nuzyra- omadacycline tablet, film coated". DailyMed. 3 June 2021. Retrieved 1 January 2024.
  3. ^ Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. (November 2015). "Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline". Antimicrobial Agents and Chemotherapy. 59 (11): 7044–53. doi:10.1128/AAC.01536-15. PMC 4604364. PMID 26349824.
  4. ^ "Drug Approval Package: Nuzyra". U.S. Food and Drug Administration (FDA). 8 November 2018. Retrieved 1 January 2024.
  5. ^ Draper MP, Weir S, Macone A, Donatelli J, Trieber CA, Tanaka SK, et al. (March 2014). "Mechanism of action of the novel aminomethylcycline antibiotic omadacycline". Antimicrobial Agents and Chemotherapy. 58 (3): 1279–83. doi:10.1128/AAC.01066-13. PMC 3957880. PMID 24041885.
  6. ^ US 7056902, Nelson ML, Ohemeng K, "4-dedimethylamino tetracycline compounds", published 6 June 2006, assigned to Paratek Pharmaceuticals Inc. 
  7. ^ Tanaka SK, Villano S (September 2016). "In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline". Antimicrobial Agents and Chemotherapy. 60 (9): 5247–53. doi:10.1128/AAC.00320-16. PMC 4997885. PMID 27324778.
  8. ^ Villano S, Steenbergen J, Loh E (October 2016). "Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections". Future Microbiology. 11 (11): 1421–1434. doi:10.2217/fmb-2016-0100. PMID 27539442.
  9. ^ Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al. (February 2014). "In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline". Antimicrobial Agents and Chemotherapy. 58 (2): 1127–35. doi:10.1128/AAC.01242-13. PMC 3910882. PMID 24295985.
  10. ^ Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, et al. (August 2017). "Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 47 (8): 682–696. doi:10.1080/00498254.2016.1213465. PMID 27499331.
  11. ^ Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD (November 2012). "A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections". Antimicrobial Agents and Chemotherapy. 56 (11): 5650–4. doi:10.1128/AAC.00948-12. PMC 3486554. PMID 22908151.
  12. ^ "Paratek Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline" (Press release). Paratek Pharmaceuticals. 3 January 2013. Retrieved 17 October 2017 – via PR Newswire.
  13. ^ Seiffert D (2015). "Paratek presents new trial data for antibiotic as late-stage trials continue". bizjournals.com. American City Business Journals. Retrieved 17 October 2017.
  14. ^ Clinical trial number NCT02378480 for "Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)" at ClinicalTrials.gov
  15. ^ "Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated" (Press release). Paratek Pharmaceuticals. 16 June 2016. Retrieved 3 July 2016 – via GlobeNewswire.
  16. ^ Clinical trial number NCT02531438 for "Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)" at ClinicalTrials.gov
  17. ^ "Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia" (Press release). Paratek Pharmaceuticals. 3 April 2017. Retrieved 16 May 2017 – via GlobeNewswire.
  18. ^ "Paratek Initiates Phase 1b Study of Omadacycline in Urinary Tract Infection" (Press release). Paratek Pharmaceuticals. 2 May 2016. Retrieved 3 July 2016 – via GlobeNewswire.
  19. ^ "Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI" (Press release). Paratek Pharmaceuticals. 15 August 2016. Retrieved 15 August 2016 – via GlobeNewswire.
  20. ^ "Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections" (Press release). Paratek Pharmaceuticals. 17 July 2017. Retrieved 19 July 2017 – via GlobeNewswire.

Read other articles:

Radicolopatia

Le informazioni riportate non sono consigli medici e potrebbero non essere accurate. I contenuti hanno solo fine illustrativo e non sostituiscono il parere medico: leggi le avvertenze. RadicolopatiaLe vertebre C5-C6, seguite da C6-C7, sono la più comune localizzazione delle radicolopatie cervicali-dorsali del colloSpecialitàneurochirurgia Classificazione e risorse esterne (EN)ICD-9-CM723.4, 724.4 e 729.2 MeSHD011843 Modifica dati su Wikidata · Manuale La radicolopatia o neuropatia ra...

 

Hendra Purnama

Hendra PurnamaInformasi pribadiNama lengkapHendra PurnamaLahir12 Januari 1997 (umur 27)Bantul, IndonesiaTinggi169 m (554 ft 6 in)Berat64 kg (141 pon) (141 pon) OlahragaNegara IndonesiaOlahragaPanahanLombaRecurve Rekam medali Panahan putra Mewakili  Indonesia Pesta Olahraga Asia Tenggara Filipina 2019 Beregu putra Filipina 2019 Perorangan putra Singapura 2015 Beregu putra Diperbarui pada 9 Desember 2019. Hendra Purnama (lahir 12 Januari 1997) adalah...

 

Asam fluoroasetat

Asam fluoroasetat Nama Nama IUPAC (preferensi) Asam fluoroasetat Nama lain Asam 2-fluoroasetatAsam monofluoroasetatMonofluoroasetatAsam fluoroetanoatAsam simonat Penanda Nomor CAS 144-49-0 Y Model 3D (JSmol) Gambar interaktif 3DMet {{{3DMet}}} Referensi Beilstein 1739053 ChEBI CHEBI:30775 ChEMBL ChEMBL509273 ChemSpider 10205670 Nomor EC Referensi Gmelin 25730 KEGG C06108 PubChem CID 5237 Nomor RTECS {{{value}}} UNII AP1JV9U41M Y Nomor UN 2642 CompTox Dashboard (EPA) DTXSID0041981 I...

Dieticyclidine

Chemical compound DieticyclidineClinical dataATC codenoneLegal statusLegal status CA: Schedule I UK: Class B Identifiers IUPAC name N,N-diethyl-1-phenylcyclohexan-1-amine CAS Number2201-19-6 YPubChem CID604690ChemSpider525655 NUNII8JY6P22UVDCompTox Dashboard (EPA)DTXSID00944617 Chemical and physical dataFormulaC16H25NMolar mass231.383 g·mol−13D model (JSmol)Interactive image SMILES CCN(CC)C1(CCCCC1)C2=CC=CC=C2 InChI InChI=1S/C16H25N/c1-3-17(4-2)16(13-9-6-10-14-16)1...

 

Würm glaciation

Last glacial period in the Alpine region This article needs to be updated. Please help update this article to reflect recent events or newly available information. Last update: 2008 chart and 1972 dating when it should be 2013 iugs chart and 2012 walker paper (see Holocene talk page) (May 2016) Violet: The extent of the Alpine ice sheet in the Würm glaciation. Blue: The extent in earlier ice ages The Würm glaciation or Würm stage (German: Würm-Kaltzeit or Würm-Glazial, colloquially often...

 

Lopud

LopudView from Sutvrač FortLopudGeographyLocationAdriatic SeaCoordinates42°41′N 17°57′E / 42.683°N 17.950°E / 42.683; 17.950ArchipelagoElaphiti IslandsArea4.63 km2 (1.79 sq mi)Highest elevation214 m (702 ft)Highest pointPolačicaAdministrationCroatiaCountyDubrovnik-NeretvaDemographicsPopulation278 (2021) Lopud (pronounced [lɔ̌pud]) is a small island off the coast of Dalmatia, southern Croatia. Lopud is economically...

Toyama Maru

Japanese ship Not to be confused with Tōya Maru. This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (July 2014) (Learn how and when to remove this template message) Toyama Maru Toyama Maru in 1941 History Japan NameToyama Maru Laid down4 August 1913 Launched20 March 1915 Completed3 June 1915 FateSunk by USS Sturgeon near T...

 

Suku Ati

AtiWanita Ati di PanayJumlah populasiperkiraan 2,000+ (1980: 1,500 penutur Ati)[1]Daerah dengan populasi signifikan FilipinaVisayasBahasaAti, Aklanon/Malaynon, Hiligaynon, Kinaray-a, Filipino, InggrisAgamaAnimisme, Kekristenan (Katolik Roma)Kelompok etnik terkaitNegrito, Bisaya Suku Ati adalah suku bangsa Negrito di Visayas di Filipina Tengah. Jumlah mereka tersebar di Pulau Boracay, Panay, dan Negros. Secara genetik, mereka identik[2] dengan suku Negrito lain seperti Suk...

 

Hi Diddle Riddle

1st episode of the 1st season of Batman Hi Diddle RiddleBatman episodeEpisode no.Season 1Episode 1Directed byRobert ButlerWritten byLorenzo Semple Jr.Production code6028-Pt. 1Original air dateJanuary 12, 1966 (1966-01-12)Guest appearancesMichael Fox Jack Barry Ben Astar, Damian O'Flynn William Dozier, Jill St. John Richard Reeves (uncredited)Special Guest Villain: Frank Gorshin as The RiddlerEpisode chronology ← Previous— Next →Smack in the Middle List ...

Ville fantôme

Pour les articles homonymes, voir La Ville fantôme et Ghost Town. Bodie, ville fantôme du sud-est californien. Une ville fantôme est une ville initialement habitée et animée qui a été abandonnée. Généralement, l'abandon d'une ville résulte du tarissement de l'activité économique qui la faisait vivre ou d'une catastrophe d'origine naturelle (désertification, inondation, séisme, éruption volcanique, etc.) ou humaine (bataille, crise économique, accident industriel, désaf...

 

List of acts of the Parliament of the United Kingdom from 1985

Part of a series onBritish law Acts of Parliament of the United Kingdom Year      1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 ...

 

McLaren P1

McLaren P1Descrizione generaleCostruttore McLaren Automotive Tipo principaleCoupé Produzionedal 2013 al 2015 Sostituisce laMcLaren F1 Sostituita daMcLaren Senna Esemplari prodotti381 (di cui 6 LM)[senza fonte] Altre caratteristicheDimensioni e massaLunghezza4588 mm Larghezza1946 mm Altezza1188 mm Passo2680 mm Massa1610 kg AltroAssemblaggioWoking, Surrey (Inghilterra) ProgettoPaul Mackenzie StileFrank Stephenson[1] Stessa famigliaMcLaren...

Ecofeminism

Approach to feminism influenced by ecologist movement French writer Françoise d'Eaubonne coined the term in a 1974 book Part of a series onGreen politics Core topics Climate change litigation Fossil fuels lobby Green politics Green party List of topics Politics of climate change Four pillars Ecological wisdom Social justice Grassroots democracy Nonviolence Perspectives Alter-globalization Bright green environmentalism Criticisms of globalization Deep ecology Degrowth Dirty hands Disinvestmen...

 

كيج هيشت

كيج هيشت   معلومات شخصية الميلاد 18 فبراير 1998 (26 سنة)[1]  الجنسية الولايات المتحدة  الحياة العملية الفرق رالي سايكلينغ (2022–)  المهنة دراج  نوع السباق سباق الدراجات الهوائية  تعديل مصدري - تعديل   كيج هيشت (بالإنجليزية: Gage Hecht)‏ هو دراج أمريكي، ولد في 18 فبرا�...

 

Greece at the 2022 Winter Olympics

Sporting event delegationGreece at the2022 Winter OlympicsFlag of GreeceIOC codeGRENOCHellenic Olympic CommitteeWebsitewww.hoc.grin Beijing, China4–20 February 2022Competitors5 (2 men and 3 women) in 2 sportsFlag bearers (opening)Apostolos AngelisMaria NtanouFlag bearer (closing)Ioannis AntoniouMedals Gold 0 Silver 0 Bronze 0 Total 0 Winter Olympics appearances (overview)193619481952195619601964196819721976198019841988199219941998200220062010201420182022 Greece competed ...

1950 Wisconsin gubernatorial election

Election 1950 Wisconsin gubernatorial election ← 1948 November 7, 1950 1952 →   Nominee Walter J. Kohler Jr. Carl W. Thompson Party Republican Democratic Popular vote 605,649 525,319 Percentage 53.21% 46.16% County resultsKohler:      50–60%      60–70%      70–80%Thompson:      50–60% Governor before election Oscar Rennebohm Republican Elected Governor W...

 

Cable One

American cable company This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: Cable One – news · newspapers · books · scholar · JSTOR (August 2020) (Learn how and when to remove this message) Cable One, Inc.Company typePublicTraded asNYSE: CABOS&P 600 componentIndustryCable TV, broadband phone, Internet, Fiber ServicesFounded1986; 38 year...

 

ليث بن أبي سليم

ليث بن أبي سليم معلومات شخصية اسم الولادة لَيْث بن أَبي سُلَيْم بن زنيم الكنية أَبُو بَكْر اللقب القرشي الحياة العملية الطبقة الطبقة الخامسة، صغار التابعين روى له روى له مُسْلِم مقرونًا بأبي إِسْحَاق الشيباني، وروى له الباقون المهنة مُحَدِّث  تعديل مصدري - تعديل   لَ...

Roza Otunbayeva

President of Kyrgyzstan from 2010 to 2011 Roza OtunbayevaРоза ОтунбаеваOtunbayeva in 20113rd President of KyrgyzstanIn office3 July 2010 – 1 December 2011Acting: 7 April 2010 – 3 July 2010Prime MinisterAlmazbek AtambayevOmurbek Babanov (Acting)Almazbek AtambayevPreceded byKurmanbek BakiyevSucceeded byAlmazbek AtambayevMinister of Foreign AffairsIn office26 February 1992 – 10 October 1992Prime MinisterTursunbek ChyngyshevPreceded byMuratbek ImanaliyevSuccee...

 

Old Europe (archaeology)

Term for a hypothetical homogeneous pre-Indo-European culture This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (April 2009) (Learn how and when to remove this message) This article possibly contains original r...